Walleye Capital
ALNY icon

Walleye Capital’s Alnylam Pharmaceuticals ALNY Stock Holding History

Walleye Capital’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.08M Buy
6,900
+1,000
+17% +$302K 0.01% 1480
2026
Q1 		$1.95M Sell
5,900
-7,500
-56% -$2.55M 0.01% 1485
2025
Q4 		$5.33M Buy
13,400
+12,200
+1,017% +$5.4M 0.02% 1111
2025
Q3 		$547K Sell
1,200
-800
-40% -$326K ﹤0.01% 2535
2025
Q2 		$652K Sell
2,000
-3,900
-66% -$1.08M ﹤0.01% 2410
2025
Q1 		$1.59M Buy
5,900
+4,800
+436% +$1.23M 0.01% 1606
2024
Q4 		$259K Sell
1,100
-18,300
-94% -$4.81M ﹤0.01% 3555
2024
Q3 		$5.34M Buy
+19,400
New +$5.05M 0.01% 1129
2024
Q2 		– Sell
-1,400
Closed -$209K – 5537
2024
Q1 		$209K Sell
1,400
-16,500
-92% -$2.75M ﹤0.01% 3950
2023
Q4 		$3.43M Buy
17,900
+6,900
+63% +$1.18M 0.01% 1370
2023
Q3 		$1.95M Buy
11,000
+10,800
+5,400% +$2.06M 0.01% 1757
2023
Q2 		$38K Sell
200
-4,100
-95% -$813K ﹤0.01% 3689
2023
Q1 		$861K Sell
4,300
-1,700
-28% -$357K 0.01% 1283
2022
Q4 		$1.43M Buy
6,000
+4,900
+445% +$1.05M 0.03% 773
2022
Q3 		$220K Buy
+1,100
New +$210K ﹤0.01% 2043
2020
Q1 		– Sell
-18,600
Closed -$2.14M – 873
2019
Q4 		$2.14M Buy
18,600
+15,500
+500% +$1.55M 0.14% 180
2019
Q3 		$249K Sell
3,100
-2,100
-40% -$166K 0.01% 1083
2019
Q2 		$377K Buy
5,200
+1,500
+41% +$115K 0.04% 634
2019
Q1 		$346K Buy
+3,700
New +$309K 0.06% 537

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Walleye Capital's ALNY Position: Q2 2026 in Review

Walleye Capital increased its Alnylam Pharmaceuticals (ALNY) stake by 20% in Q2 2026, buying an estimated $156K and bringing the position to 3,155 shares worth $950K. The position accounts for ﹤0.01% of the portfolio, ranked #2173.

Walleye Capital first reported a position in ALNY in Q3 2018 and has held it in 16 quarters since. The position peaked at $17.1M in Q2 2024. 791 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Walleye Capital held 3,155 shares of Alnylam Pharmaceuticals worth $950K as of Q2 2026.
  • Walleye Capital bought 516 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $156K.
  • Alnylam Pharmaceuticals made up ﹤0.01% of Walleye Capital's portfolio in Q2 2026, its #2173 holding.
  • Walleye Capital first reported a position in Alnylam Pharmaceuticals in Q3 2018 and has held it in 16 quarters since.
  • Walleye Capital's Alnylam Pharmaceuticals position peaked at $17.1M in Q2 2024.
  • 791 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Walleye Capital's 13F filing for Q2 2026, filed 3 Aug 2026.